MALT lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:
{{familytree |boxstyle=background: #DCDCDC;| | | | | | | B01 | | | | | | | | | | B02 |B01=<div style="width: 12em; padding:0em;">'''Early stage<br>(localized)<br>''' </div>|B02=<div style="width: 12em; padding:0em;">'''Advanced stage'''</div>}}
{{familytree |boxstyle=background: #DCDCDC;| | | | | | | B01 | | | | | | | | | | B02 |B01=<div style="width: 12em; padding:0em;">'''Early stage<br>(localized)<br>''' </div>|B02=<div style="width: 12em; padding:0em;">'''Advanced stage'''</div>}}
{{familytree |boxstyle=background: #DCDCDC;| | | | | | | |!| | | | | |,|-|-|-|v|-|^|-|v|-|-|-|.|}}
{{familytree |boxstyle=background: #DCDCDC;| | | | | | | |!| | | | | |,|-|-|-|v|-|^|-|v|-|-|-|.|}}
{{familytree |boxstyle=background: #DCDCDC;| | | | | | | |!| | | | | C01 | | C02 | | C03 | | C04 |C01=<div style="width: 9em; padding:0.2em;">'''[[Fibrillary astrocytoma]]''' </div>|C02=<div style="width: 9em; padding:0.2em;">'''[[Gemistocytic astrocytoma]]'''</div>|C03=<div style="width: 9em; padding:0.2em;">'''[[Protoplasmic astrocytoma]]'''</div>|C04=<div style="width: 9em; padding:0.2em;">'''[[Oligoastrocytoma]]'''</div>}}
{{familytree |boxstyle=background: #DCDCDC;| | | | | | | |!| | | | | C01 | | C02 | | C03 | | C04 |C01=<div style="width: 9em; padding:0.2em;">'''Observation''' </div>|C02=<div style="width: 9em; padding:0.2em;">'''Radiotherapy'''</div>|C03=<div style="width: 9em; padding:0.2em;">'''Chemotherapy'''</div>|C04=<div style="width: 9em; padding:0.2em;">'''Monoclonal antibodies'''</div>}}
{{familytree |boxstyle=background: #DCDCDC;| |,|-|-|-|v|-|^|-|v|-|-|-|v|-|-|-|.|}}
{{familytree |boxstyle=background: #DCDCDC;| |,|-|-|-|v|-|^|-|v|-|-|-|v|-|-|-|.|}}
{{familytree |boxstyle=background: #DCDCDC;| D01 | | D02 | | D03 | | D04 | | D05 |D01=<div style="width: 9em; padding:0.2em;">'''Antibiotic therapy''' </div>|D02=<div style="width: 9em; padding:0.2em;">'''Radiation therapy'''</div>|D03=<div style="width: 9em; padding:0.2em;">'''Surgery'''</div>|D04=<div style="width: 9em; padding:0.2em;">'''Chemotherapy'''</div>|D05=<div style="width: 9em; padding:0.2em;">'''Monoclonal antibodies'''</div>}}
{{familytree |boxstyle=background: #DCDCDC;| D01 | | D02 | | D03 | | D04 | | D05 |D01=<div style="width: 9em; padding:0.2em;">'''Antibiotic therapy''' </div>|D02=<div style="width: 9em; padding:0.2em;">'''Radiation therapy'''</div>|D03=<div style="width: 9em; padding:0.2em;">'''Surgery'''</div>|D04=<div style="width: 9em; padding:0.2em;">'''Chemotherapy'''</div>|D05=<div style="width: 9em; padding:0.2em;">'''Monoclonal antibodies'''</div>}}

Revision as of 20:43, 27 January 2016

MALT lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating MALT Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Upper GI Endoscopy

CT

MRI

Endoscopic Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

MALT lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of MALT lymphoma medical therapy

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onMALT lymphoma medical therapy

CDC on MALT lymphoma medical therapy

MALT lymphoma medical therapy in the news

on MALT lymphoma medical therapy

Directions to Hospitals Treating MALT lymphoma

Risk calculators and risk factors for MALT lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Medical therapy

The various treatment options for MALT lymphoma include:

 
 
 
 
 
 
 
 
 
 
 
 
Treatment of MALT lymphoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Early stage
(localized)
 
 
 
 
 
 
 
 
 
Advanced stage
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation
 
Radiotherapy
 
Chemotherapy
 
Monoclonal antibodies
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibiotic therapy
 
Radiation therapy
 
Surgery
 
Chemotherapy
 
Monoclonal antibodies

If the disease is limited to the stomach (which is assessed with computed tomography), then 70-80% of patients will have a complete regression on treatment with antibiotic eradication of H. pylori. [1]

Radiotherapy

Others may be effectively controlled with the use of radiotherapy, or surgery. Both modalities may be curative in localized disease.

Chemotherapy

In contrast, if the disease has spread or has been refractory on antibiotics, chemotherapy may need to be considered.

References

  1. Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M (1995). "Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group". Lancet. 345 (8965): 1591–4. PMID 7783535.


Template:WikiDoc Sources